STOCK TITAN

10x Genomics to Report First Quarter Financial Results on May 4, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

10x Genomics (Nasdaq: TXG) will report its financial results for Q1 2022 after market close on May 4, 2022. A conference call to discuss these results, along with business developments and future outlook, will begin at 1:30 p.m. PT / 4:30 p.m. ET. The live audio of the webcast will be accessible through the company's website and archived for 45 days. 10x Genomics focuses on life science technology advancements, with significant adoption in top global research institutions and pharmaceutical companies.

Positive
  • Company will release Q1 2022 financial results, providing insights into performance.
  • Strong adoption of products by top global research institutions and pharmaceutical companies.
Negative
  • None.

PLEASANTON, Calif., April 7, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,300 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 1,300 issued patents and patent applications.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Media Contact:
media@10xgenomics.com

Investor Relations Contact:
investors@10xgenomics.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-first-quarter-financial-results-on-may-4-2022-301520307.html

SOURCE 10x Genomics, Inc.

FAQ

When will 10x Genomics report its Q1 2022 financial results?

10x Genomics will report its Q1 2022 financial results on May 4, 2022.

What time is the conference call for 10x Genomics' Q1 2022 results?

The conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

How can I access the webcast for 10x Genomics' financial results?

The live audio of the webcast can be accessed via the 'Investors' section of the 10x Genomics website.

What is the focus of 10x Genomics as a company?

10x Genomics is dedicated to building life science technology products for biological analysis to advance human health.

10x Genomics, Inc.

NASDAQ:TXG

TXG Rankings

TXG Latest News

TXG Stock Data

1.68B
103.97M
2.17%
94.44%
6.28%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
PLEASANTON